Skip to content
ES
MARKETS / NASDAQ / IBIO
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

iBio, Inc. IBIO

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$100,000
▼ 75.0% YoY
$-33.0M
$-23.8M
In brief

What this company does

Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop. We are developing second-generation therapies to meet these unmet needs, using the power of AI-guided antibody design and advanced screening technologies. We anticipate the commencement of our first human clinical trials in late fiscal 2026 or early fiscal 2027. Our discovery and development work is conducted at our San Diego research and development (“R&D”) laboratory space, where our AI and ML scientists and biopharma researchers operate side by side.

Written from the business description in iBio, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 September 2025. Every sentence was checked against that document before publication.

Growth
USD 100,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.1 · Net income -33.0
-25.0M-50.0M201020122014201620182020202220242025
Compound annual growth
−46.9%
−20.1%
−10.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −46.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−33044 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -35141.0% · Net -33044.0%
-20000%-40000%201020122014201620182020202220242025
ROE
FY2025 · ROE -65.7%
-500%-1000%-1500%201020122014201620182020202220242025
Gross margin—
Operating margin-35141.0%
Net margin-33044.0%
Return on assets-54.0%
EBITDAUSD -34.6M

Each USD of equity lost 66 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -23.8
-20M-40M201020122014201620182020202220242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 99.1M
EquityUSD 85.7M
CashUSD 56.4M
Current ratio7.85×

Equity funds 86% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0·
Net income $B−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.32−1.75−6.50−106.19−5.78−3.00−0.61−0.94−1.54−1.64−0.12−0.09−0.06−0.13−0.14−0.39
Dividend / sh $················
Payout %················
ROE %−65.7−101.5−135.7−164.9−58.5−28.1−55.6−188.9−128.4−154.2−92.3−76.5−65.7−110.3−178.4−1909.0
Shares out B0.060.020.010.000.010.000.000.020.020.010.090.080.070.060.050.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 27 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image